PEDIATRIC. BRAIN ACNS 0332: Efficacy of Carboplatin Administered Concomitantly with Radiation and Isotretinoin as a COMPANION STUDIES
|
|
|
- Daniela Maxwell
- 6 years ago
- Views:
Transcription
1 PEDIATRIC BRAIN ACNS 0332: Efficacy of Carboplatin Administered Concomitantly with Radiation and Isotretinoin as a Pro-Apoptotic Agent in other than Average Risk Medulloblastoma/PNET Patients. ACNS 02B3: Children's Oncology Group (COG) Protocol for Collecting and Banking Pediatric Brain Tumor Research Specimens. ACNS 0831: Randomized Trial of Post-Radiation Chemotherapy in Patients with newly Diagnosed Ependymona Ages 1-21 Years: A Group wide Phase III Study. ACNS 1123: Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors (CNS-GCT). COMPANION STUDIES ACCRN 07: Protocol for the Enrollment on the Official COG Registry, the Childhood Cancer Research Network (CCRN). gistry&rank=1 POG 9902: COG Soft Tissue Sarcoma Diagnosis, Biology and Banking Protocol.
2 ABTR 01B1: COG Protocol for Collecting and Banking Pediatric Research Specimens Including Rare Pediatric Tumors. ALTE 07C1: Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children with Cancer. ALTE 1621: Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Heart Failure (PREVENT-HF): A Phase 2b Randomized Placebo-Controlled (Carvedilol) Trial CANCER CONTROL ALTE 05N1: Umbrella Long-Term Follow-Up Protocol. NEUROBLASTOMA & OTHER EMBRYONAL TUMORS ANBL 00B1: Neuroblastoma Biology Studies. ANBL1221: Randomized Trial of Irinotecan/Temozolomide with Temsirolimus (NSC# , IND# 61010) or Chimeric Antibody (ch14.18) (NSC# , IND# 4308) in Children with Refractory, Relapsed or Progressive Neuroblastoma. ANBL1232: Utilizing Response and Biology-Based Risk Factors to Guide Therapy in Patients with Non- High-Risk Neuroblastoma.
3 LYMPHOMAS/HODGKIN S DISEASE AHOD1331: Randomized Study of Brentuximab Vedotin (SGN-35, IND # ) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (chl) in Children and Adolescents. ANHL12P1: Randomized Trial of Brentuximab Vedotin (SGN35, NSC# ), or Crizotinib (NSC# , commercially labeled) in Combination with Chemotherapy for Newly Diagnosed Patients with Anaplastic Large Cell Lymphoma (ALCL). NATIONAL WILM S TUMOR STUDY POG 9442: National Wilms Tumor Late Effects Study. AREN03B2: Renal tumors Classification, Biology, and Banking Study. HEPATOBLASTOMA TUMORS AHEP 0731: Treatment of Children with All Stages of Hepatoblastoma. MULTI DISEASE SITES ADVL 1522: Study of IMGN901 (Lorvotuzumab Mertansine; IND# , NSC# ) in Children with Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor (MPNST) and Synovial Sarcoma.
4 APEC 14B1: The Project: Every Child Protocol: A Registry, Eligibility Screening, Biology and Outcome Study. BONE & SOFT TISSUE SARCOMAS AOST 06B1: A Children's Oncology Group Protocol for Collecting and Banking Osteosarcoma Specimens. AEWS 07B1: A Children's Oncology Group Protocol for Collecting and Banking Ewing Sarcoma Specimens. AEWS 1031: Randomized Trial of Adding Vincristine-topotecan-cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-metastatic Ewing Sarcoma. AEWS 1221: Randomized Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# , IND # ) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma. AOST 1321: Phase 2 Study of Denosumab (IND#127430, NSC# ), a RANK Ligand Antibody, for Recurrent or Refractory Osteosarcoma ARST 1321: Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS), a Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# , IND# )
5 LEUKEMIA (ALL) AALL 05B1: COG Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens. AALL 08B1: Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL). AALL 0932: Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B- ALL) or Localized B-lineage Lymphoblastic Lymphoma (B-LLy). AALL 1131: Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (B-ALL) Testing Clofarabine (IND# 73789, NSC# ) in the Very High Risk Stratum Including a stratum evaluating Dasatinib (IND# 73789, NSC# ) in patients w/ Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations AALL 1231: Randomized Trial Investigating Bortezomib (NSC# ; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T- Lymphoblastic Lymphoma (T-LLy). AALL 1331: Risk-Stratified Randomized Testing of Blinatumomab (IND# , NSC# ) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL) LEUKEMIA (AML) AAML 08B1: Biology Study of Transient Myeloproliferative Disorder (TMD) in Children with Down Syndrome (DS).
6 AAML 1031: Randomized Trial for Patients with de novo AML Using Bortezomib and Sorafenib (IND# ; NSC# ; NSC# ) for Patients with High Allelic Ratio FLT3/ITD. AAML 1331: A Phase III Study for Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APL) using Arsenic Trioxide and All-Trans Retinoic Acid AAML 1531: Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome (DS).
CURRENTLY ENROLLING ONCOLOGY TREATMENT STUDIES (as of )
Leukemia AALL0932 closed after Induction CURRENTLY ENROLLING ONCOLOGY TREATMENT STUDIES (as of 10.10.2017) Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized
CURRENTLY ENROLLING ONCOLOGY TREATMENT STUDIES (as of 4/27/2017)
CURRENTLY ENROLLING ONCOLOGY TREATMENT STUDIES (as of 4/27/2017) Leukemia AALL0932 closed after Induction Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized
Contacts. Catherine Aftandilian, MD, MS Norman Lacayo, MD Gary Dahl, MD. Sheri Spunt, MD, MBA. Crystal Mackall, MD Kara Davis, DO
and Clinical Trials: Hematology, Oncology, and Stem Cell Transplantation Contacts General Inquiries Baggott, RN, PhD AML, ALL Bone and Soft Tissue Sarcomas, Renal Tumors Catherine Aftandilian, MD, MS,
Hem/Onc/BMT Open and Enrolling Clinical Trials
Hem/Onc/BMT Open and Enrolling Clinical Trials PROTOCOL ID DISEASE PROTOCOL TITLE PI ELIGIBILITY CRITERIA Pfizer Apixaban DVT Apixaban B0661037, A Randomized, Open-Label, Active Controlled, Safety and
Contacts. Catherine Aftandilian, MD, MS Gary Dahl, MD Norman Lacayo, MD. Allison Pribnow, MD Sheri Spunt, MD, MBA
and Clinical Trials: Hematology, Oncology, and Stem Cell Transplantation Contacts General Inquiries: Oncology Christina Baggott, RN, PhD General Inquiries: Hematology Elaine Macasiray, RN AML, ALL Catherine
5/8/2015. Disclosures. Personalized Medicine & Pediatric Oncology: Is the Future Here Yet? Objectives
Disclosures Personalized Medicine & Pediatric Oncology: Is the Future Here Yet? Richard Drachtman, MD NJAAP Annual Conference May 13, 2015 Research Support: Mast, Astra Zeneca, Jazz, Novartis, Pfizer Objectives
Sarcomas. Living Beyond Cancer A-Z UT Health San Antonio MD Anderson Cancer Center
Sarcomas Living Beyond Cancer A-Z UT Health San Antonio MD Anderson Cancer Center Aaron Sugalski, DO Associate Professor of Pediatric Hematology/Oncology Medical Director, UHS Pediatric Blood and Cancer
Shared Care & Survival CTYA SSCRG (Childhood Cancer Research Group)
Shared Care & Survival CTYA SSCRG (Childhood Cancer Research Group) January 2013 The NCIN is a UK-wide initiative, working to drive improvements in standards of cancer care and clinical outcomes by improving
TARGETED THERAPY FOR CHILDHOOD CANCERS
TARGETED THERAPY FOR CHILDHOOD CANCERS AZIZA SHAD, MD AMEY DISTINGUISHED PROFESSOR OF PEDIATRIC HEMATOLOGY ONCOLOGY, BLOOD AND MARROW TRANSPLANTATION LOMBARDI CANCER CENTER GEORGETOWN UNIVERSITY HOSPITAL
New Surgical Oncology Clinic at Nationwide Children s Hospital
Hematology/Oncology & BMT New Surgical Oncology Clinic at Nationwide Children s Hospital This clinic offers convenient, comprehensive care for patients with cancer. Here, in one visit, pediatric patients
Corporate Medical Policy
Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for Solid Tumors of File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_solid_tumors_childhood
Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December
Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December 17 2010. 32/10 Imatinib for gastrointestinal stromal tumours (unresectable/metastatic) (update on
HSHS St. Vincent Hospital Regional Cancer Center Adult Active Study List
NHLBI-MDS ECOG-A NCT02775383 Blood Disorders-Other The National Myelodysplastic Syndromes (MDS) Study A221101 ALLIANCE NCT01781468 Brain A Phase III Randomized, Double-Blind Placebo Controlled Study of
Declining Childhood and Adolescent Cancer Mortality
Declining Childhood and Adolescent Cancer Mortality Malcolm A. Smith, MD, PhD 1 ; Sean F. Altekruse, DVM, PhD 2 ; Peter C. Adamson, MD 3 ; Gregory H. Reaman, MD 4 ; and Nita L. Seibel, MD 1 BACKGROUND:
Our Clinical Trials. Oncology
Our Clinical Trials Oncology ANGIOGENESIS Trebananib (AMG 86) (angiopoietin inhibitor) ANTIBODY DRUG CONJUGATE, continued AMG 595 (anti-egfrviii) Trebananib With Paclitaxel and Trastuzumab or Capecitabine
Open / Closed to Recruitment. POSCU Involvement. Diagnosis Trial Oral Chemo Protocol Title Bone
This list covers the Principal Treatment Centre (Alder Hey) and POSCUs including community services. It covers solid tumour oncology and haemato oncology clinical management protocols and agreed chemotherapy
An international clinical program for the diagnosis and treatment of children, adolescents and young adults with ependymoma
This list covers the Principal Treatment Centre (Alder Hey) and POSCUs including community services. It covers solid tumour oncology and haemato-oncology clinical management protocols and agreed chemotherapy
FAST FACTS Eligibility Reviewed and Verified By MD/DO/RN/LPN/CRA Date MD/DO/RN/LPN/CRA Date Consent Version Dated
Page 1 of 5 COG-AEWS1221: Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND# 120449) to Multiagent Chemotherapy for Patients with Newly
Challenges in studying risk factors for childhood cancer
Challenges in studying risk factors for childhood cancer Julie A. Ross, Ph.D. Professor and Director, Division of Epidemiology & Clinical Research Department of Pediatrics, University of Minnesota & Masonic
Paediatric Strategy Forum A new concept proposed by ACCELERATE
A new concept proposed by ACCELERATE 1 2 s Objective - provide a unique opportunity for interaction between all stakeholders (regulators, pharmaceutical companies, clinical and researcher academics and
Methoden / Methods inc. ICCC-3 105
Methoden / Methods inc. ICCC-3 105 Internationale Klassifikation der Krebserkrankungen bei Kindern (ICCC-3) Zuordnung von ICD-O-3-Codes für Morphologie und Topographie zu diagnostischen Kategorien International
HSHS St. Vincent Hospital Regional Cancer Center Adult Active Study List
A031501 ALLIANCE NCT03244384 Bladder Phase III Randomized Adjuvant study of MK-3475 (Pembrolizumab) in muscle invasive and locally advanced urothelial carcinoma (AMBASSADOR) Versus Observation NHLBI-MDS
FAST FACTS Eligibility Reviewed and Verified By MD/DO/RN/LPN/CRA Date MD/DO/RN/LPN/CRA Date Consent Version Dated
Page 1 of 8 COG-AALL1131: A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (IND#73789, NSC#732517) in Patients with Ph-like
Effective local and systemic therapy is necessary for the cure of Ewing tumor Most chemotherapy regimens are a combination of cyclophosphamide,
Ewing Tumor Perez Ewing tumor is the second most common primary tumor of bone in childhood, and also occurs in soft tissues Ewing tumor is uncommon before 8 years of age and after 25 years of age In the
CLIC Sargent Eligibility Criteria
1 Eligibility Criteria DOCUMENT GOVERNANCE: Eligibility criteria Produced by J. Hawkins & Grants Team Sponsored by Dara de Burca Version Approval by Executive Team 10 th June 2014 Board of Trustees 3 rd
SPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS
SPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS (Filgrastim, Capecitabine, Imatinib, Dasatinib, Erolotinib, Sunitinib, Pazopanib, Fludarabine, Sorafenib, Crizotinib, Tretinoin, Nilotinib,
National Cancer Drugs Fund List - Approved
National Cancer Drugs Fund List - Approved DRUG Abiraterone Aflibercet Albumin Bound Paclitaxel Axitinib CDF INDICATION (EXCLUDING APPROVED CRITERIA ) Metastatic Prostate Cancer Metastatic Colorectal Cancer
Open Trials as of end of March 2016
EORTC 10085 PRO EORTC 10085 prospective part, Clinical and biological characterization of Male Breast Cancer: an international EORTC, BIG and NABCG inter study 30 30-Jun-2016 estelle.cassoly@sakk.ch IBCSG
CancerPACT Cancer Patients Alliance for Clinical Trials
TM CancerPACT Cancer Patients Alliance for Clinical Trials Listing of Cancer Clinical Trials in the Sacramento Area Summer 2008 I. Solid Tumors 1. Breast p.1 2. Central Nervous System p.3 3. Gastrointestinal
CHILDHOOD CANCER SURVIVOR STUDY ANALYSIS CONCEPT PROPOSAL
CHILDHOOD CANCER SURVIVOR STUDY ANALYSIS CONCEPT PROPOSAL 1. Study title: Subsequent neoplasms among survivors of childhood cancer not previously treated with radiation 2. Working group and investigators:
Pediatric cancer. Kleebsabai Sanpakit, MD. Hemato/Oncology division, Department of Pediatrics Faculty of Medicine Siriraj hospital
Pediatric cancer เทคน คการให รห สโรค Siriraj Cancer ICD-O Registry ฉบ บม ออาช พ Kleebsabai Sanpakit, MD. Hemato/Oncology division, Department of Pediatrics Faculty of Medicine Siriraj hospital Different
CLINICAL TRIALS ACC. Jul 2016
CLINICAL TRIALS ACC Jul 2016 Glioblastoma BRAIN A071102 A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Introduction to Pediatric Neoplasms
Introduction to Pediatric Neoplasms F C D S E D U C A T I O N A L W E B C A S T S E R I E S S T E V E N P E A C E, B S, C T R / M A Y R A E S P I N O, B A, R H I T, C T R J A N U A R Y 1 7, 2 0 1 3 1 Program
TUESDAY, 18th OCTOBER, 2016 / DAY -2
Legend: Keynote Educational PODC Symposium Meet the Expert (MTE) Paediatric Psycho-Oncology () Opening/Closing Award Session Free Paper Session (FPS) Session Satellite Symposium SIOPe GA SIOP ABM Late
MEDICAL PRIOR AUTHORIZATION
MEDICAL PRIOR AUTHORIZATION TAXOTERE (docetaxel) DOCEFREZ(docetaxel) docetaxel (generic) POLICY I. INDICATIONS The indications below including FDA-approved indications and compendial uses are considered
1/15/2013. Introduction to Pediatric Neoplasms. Program Outline. Introduction
Introduction to Pediatric Neoplasms F C D S E D U C A TI O N A L WE B C A S T S E R I E S ST E VE N P E A C E, B S, C T R / MA Y R A E SP I N O, B A, R H I T, C T R J A N U A R Y 1 7, 2 0 1 3 1 Program
Future Targets for Acute Myeloid Leukemia
Future Targets for Acute Myeloid Leukemia E. Anders Kolb, M.D. Director, Nemours Center for Cancer and Blood Disorders Chair, Children s Oncology Group Myeloid Disease Committee Future Targets for Acute
Pediatric Cancer in Idaho,
Pediatric Cancer in Idaho, 1996-2006 Although relatively rare in comparison with cancer in older adults, cancer is the second leading cause of death in persons aged 1-14 years. The epidemiology of cancer
Proceedings of Congress
HK J Paediatr (new series) 2012;17:123-129 Proceedings of Congress 2011 Annual Scientific Meeting: Hong Kong Paediatric Haematology and Oncology Study Group 26 March 2011 Acute Lymphoblastic Leukaemia
TUESDAY, 18th OCTOBER, 2016 / DAY -2. THE SPENCER HOTEL Hall A Hall B (St. Lukes Hospital)
Legend: Keynote Educational Meet the Expert (MTE) Paediatric Psycho-Oncology () Opening/Closing Award Session Free Paper Session (FPS) Session Satellite SIOPe GA SIOP ABM Late Breaker Session Networking
28 OI November December A Medical Home for Adolescents and Young Adults with Cancer
28 OI November December 2013 www.accc-cancer.org A Medical Home for Adolescents and Young Adults with Cancer By Douglas S. Hawkins, MD Our team consists of more than 30 doctors specializing in cancers
Keytruda (pembrolizumab)
Keytruda (pembrolizumab) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 10/01/2015 Current Effective Date: 07/24/2017TBD03/01/2018 POLICY A. INDICATIONS The
Assessing quality of life in sarkoma trials
Pan-European Clinical Trials under current EU regulations: A training course for data managers, study nurses, and junior clinical investigators London, January 24/25, 2008 Assessing quality of life in
Lessons from treatment of pediatric sarcomas at difficult sites. Dr. Andrea Ferrari Pediatric Oncology Unit Istituto Nazionale Tumori, Milan, Italy
Lessons from treatment of pediatric sarcomas at difficult sites Dr. ndrea Ferrari Pediatric Oncology Unit stituto Nazionale Tumori, Milan, taly Disclosure slide have no potential conflicts of interest
UK Musculoskeletal Oncology: Something for All Ages. Lars Wagner, MD Pediatric Hematology/Oncology University of Kentucky
UK Musculoskeletal Oncology: Something for All Ages Lars Wagner, MD Pediatric Hematology/Oncology University of Kentucky Pediatric-Type Sarcomas of Bone and Soft Tissue The incidence of sarcoma continues
Treatment of Paediatric Cancers in Hong Kong: An Interim Report
HK J Paediatr (new series) 2001;6:110-115 in Hong Kong: An Interim Report CK LI, GCF CHAN, KW CHIK, SY HA, YL LAU, ACW LEE, CY LEE, CK LI, SC LING, CW LUK, MMK SHING, HL YUEN, PMP YUEN Abstract Key words
PEDIATRIC CANCER IN IDAHO
PEDIATRIC CANCER IN IDAHO 2001-2010 May 2013 A Publication of the ACKNOWLEDGMENTS The Idaho Hospital Association (IHA) contracts with, and receives funding from, the Idaho Department of Health and Welfare,
Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma
Karmanos offers clinical trials for many different forms of cancer. Below are the most current clinical trials open to new participants as of this publication's issue date. If you have any questions regarding
Acknowledgements and Disclaimer
Infant Cancers in California, 1988 2011 Acknowledgements and Disclaimer The collection of cancer incidence data used in this study was supported by the California Department of Public Health as part of
SCIENTIFIC TIMETABLE SIOP 2015
SCIENTIFIC TIMETABLE SIOP 2015 September, 2015 WEDNESDAY, 7 TH OCTOBER 2015 / DAY 2 1.43 09:30 SIOP Committee 12:00 SIOP Essential Drugs Working 13:00 SIOP Work (Open) 14:00 Nurse Researchers 16:00 17:00
SHEDDING A LITTLE LIGHT ON THE BIGGER PROBLEM
NationalPCF.org SHEDDING A LITTLE LIGHT ON THE BIGGER PROBLEM 1.7 MILLION NEW CANCER CASES EVERY YEAR 600,000 PEOPLE WILL DIE More than of those who survive childhood cancer will have a significant health
Cancer: Can we Afford the Cure? Current Trends in Oncology Treatment
Cancer: Can we Afford the Cure? Current Trends in Oncology Treatment Julie Kennerly-Shah, PharmD, MS, MHA, BCPS May 30, 2018 The Ohio State University Comprehensive Cancer Center Arthur G. James Cancer
H&HD ANTINEOPLASTIC DRUG CARD ASSEMBLY INSTRUCTIONS
H&HD ANTINEOPLASTIC DRUG CARD ASSEMBLY INSTRUCTIONS Each of you should have 37 new cards: 7 orange cards for antimetabolites 11 white cards for miscellaneous drugs (2 DNA synthesis inhibitors, 1 enzyme,
Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma
Karmanos offers clinical trials for many different forms of cancer. Below are the most current clinical trials open to new participants as of this publication's issue date. If you have any questions regarding
Advances in paediatric cancer treatment
Review Article Advances in paediatric cancer treatment Federica Saletta 1,2, Michaela S. Seng 2, Loretta M.S. Lau 1,2,3 1 Children s Cancer Research Unit, Kid s Research Institute, The Children s Hospital
Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma
Karmanos offers clinical trials for many different forms of cancer. Below are the most current clinical trials open to new participants as of this publication's issue date. If you have any questions regarding
ASSESSMENT OF THE PAEDIATRIC NEEDS CHEMOTHERAPY PRODUCTS (PART I) DISCLAIMER
European Medicines Agency Evaluation of Medicines for Human Use London, September 2006 Doc. Ref.: EMEA/384641/2006 ASSESSMENT OF THE PAEDIATRIC NEEDS CHEMOTHERAPY PRODUCTS (PART I) DISCLAIMER The Paediatric
PEDIATRIC CANCER IN IDAHO
PEDIATRIC CANCER IN IDAHO 1999-2008 May 2011 A Publication of the ACKNOWLEDGMENTS The Idaho Hospital Association (IHA) contracts with, and receives funding from, the Idaho Department of Health and Welfare,
HSHS St. Vincent Hospital Regional Cancer Center Adult Active Study List
NHLBI-MDS ECOG-A NCT02775383 Blood Disorders-Other The National Myelodysplastic Syndromes (MDS) Study PNH Registry M07-001 DRUG CO NCT01374360 Blood Disorders-Other PNH Registry A071102 ALLIANCE NCT02152982
Johann Hitzler, MD, FRCPC, FAAP Jacqueline Halton, MD, FRCPC Jason D. Pole, PhD
Photo by Tynan Studio Johann Hitzler, MD, FRCPC, FAAP Jacqueline Halton, MD, FRCPC Jason D. Pole, PhD 96 Atlas of Childhood Cancer in Ontario (1985-2004) Chapter 6: Leukemia 6 Leukemia Atlas of Childhood
Recommended Timing for Transplant Consultation
REFERRAL GUIDELINES Recommended Timing for Transplant Consultation Published jointly by the National Marrow Donor Program /Be The Match and the American Society for Blood and Marrow Transplantation BeTheMatchClinical.org
RESEARCH COMMUNICATION. Childhood Cancer Incidence and Survival , Thailand: Study from the Thai Pediatric Oncology Group
Childhood Cancer Incidence and Survival 2003-2005, Thailand RESEARCH COMMUNICATION Childhood Cancer Incidence and Survival 2003-2005, Thailand: Study from the Thai Pediatric Oncology Group Surapon Wiangnon
Xerocept for Control of Tumor or Radiation Mediated Swelling /I-II Mark W. Kieran, MD, PhD
Treatment Area Study Name ID Number/ Phase BRAIN TUMORS Brain Tumor Imaging Recurrent Brain Tumors A Pilot Non-Therapeutic Neuro-Imaging Study of 18F-FLT in Pediatric Patients with Newly Diagnosed Central
Active Cancer Studies by Approval Date For additional information on any one of these studies contact the Lancaster General Cancer Center
Active Cancer Studies by Approval Date For additional information on any one of these studies contact the Lancaster General Cancer Center 717-544-3113 PROTOCOL NO STUDY TITLE PRINCIPAL INVESTIGATOR ECOG
Epidemiology of AYA tumours. Dan Stark, MD Consultant in Medical Oncology Leeds UK
Epidemiology of AYA tumours Dan Stark, MD Consultant in Medical Oncology Leeds UK Summary Why we should study the epidemiology of AYA tumours What is already known What is not already known and is important
OVERVIEW OF COMMENTS RECEIVED ON LIST OF PAEDIATRIC NEEDS ONCOLOGY I (CYTOTOXIC THERAPY)
European Medicines Agency Evaluation of Medicines for Human Use London, September 2006 Doc. Ref. OVERVIEW OF COMMENTS RECEIVED ON LIST OF PAEDIATRIC NEEDS ONCOLOGY I (CYTOTOXIC THERAPY) Table 1: Organisations
Significant Papers in Pediatric Oncology: Phase I Studies Current Status and Future Directions
Significant Papers in Pediatric Oncology: Phase I Studies Current Status and Future Directions Susannah E. Koontz, PharmD, BCOP Clinical Pharmacy & Education Consultant Pediatric Hematology/Oncology and
Radiation Oncology Study Guide
Radiation Oncology Study Guide For the Initial CertificationQualifying (Computer-Based) Examination General and Radiation Oncology This examination is designed to assess your understanding of the entire
Peking University People's Hospital, Peking University Institute of Hematology
Qian Jiang, M.D. Peking University People's Hospital, Peking University Institute of Hematology No. 11 Xizhimen South Street, Beijing, 100044, China. Phone number: 86-10-66583802 Mobile: 86-13611115100
Subspecialty Inpatient Rotation: Pediatric Oncology at Memorial Sloan Kettering Cancer Center Senior Resident
Subspecialty Inpatient Rotation: Pediatric Oncology at Memorial Sloan Kettering Cancer Center Senior Resident Residents: Pediatric residents at the PL3 level Prerequisites: Successful completion or waiver
1. Background & Scope 3
Birmingham Children s Hospital Primary treatment centre (PTC) list of protocols and guidelines which contain approved cytotoxic chemotherapy regimens Updated 9 th June 2016 (Jason Patel) Contents 1. Background
Diagnosis Place of delivery Proforma
STCYPCNG List of chemotherapy regimens Day Localised Unresectable neuroblastoma (CCLG guidelines) Carbo-Etoposide Etoposide CADO Doxorubin, Vincristine Irinotecan, Irinotecan-TMZ temozolomide Localised
Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma
Karmanos offers clinical trials for many different forms of cancer. Below are the most current clinical trials open to new participants as of this publication's issue date. If you have any questions regarding
Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma
Karmanos offers clinical trials for many different forms of cancer. Below are the most current clinical trials open to new participants as of this publication's issue date. If you have any questions regarding
KYMRIAH (tisagenlecleucel)
KYMRIAH (tisagenlecleucel) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and
Childhood cancer survival : Dr. Behçet Uz Children s Hospital registry
Turkish Journal of Cancer Vol.30/ No. 2/2000 Childhood cancer survival 1990-1997: Dr. Behçet Uz Children s Hospital registry ÖZNUR DÜZOVALI 1, RAGIP ORTAÇ 2, İRFAN KARACA 3, NAZİHAT ARGON 4, YASEMİN USLU
OPEN TRIALS Accruals counted until 30-April Current Accrual
Disease group Breast OPEN TRIALS Trial Title Accrual Target IBCSG 48-14 POSITIVE IBCSG 50-14 OLYMPIA IBCSG 52-15 PALLAS SAKK 21/12 A study evaluating the pregnancy outcomes and safety of interrupting endocrine
Childhood cancer registration in England: 2015 to 2016
Childhood cancer registration in England: 2015 to 2016 Report on behalf of the Children, Teenagers and Young Adults Site Specific Clinical Reference Group, National Cancer Registration and Analysis Service
10/7/2014. I have no conflicts of interest I will discuss drugs used for non-fda approved causes
Stuart H. Gold The University of North Carolina at Chapel Hill October 3, 2014 I have no conflicts of interest I will discuss drugs used for non-fda approved causes 1 Pediatric oncology cooperative groups
Introduction Pediatric malignancies Changing trends & Radiation burden Radiation exposure from PET/CT Image gently PET & CT modification - PET/CT
Introduction Pediatric malignancies Changing trends & Radiation burden Radiation exposure from PET/CT Image gently PET & CT modification - PET/CT protocols Tips Leukaemia / lymphoma: ~ 35% acute lymphoblastic
The adolescents and young adults population (AYA) has
ORIGINAL ARTICLE Survival Analysis After Diagnosis With Malignancy of Egyptian Adolescent Patients: A Single-center Experience Azza A. G. Tantawy, MD,* Nayera H. K. El Sherif, MD,* Fatma S. E. Ebeid, MD,*
The medical team consists of 2 Hemato-Oncologists pediatrician and 6 Hematologists pediatricians.
Dr. Robert Reid Cabral Children s Hospital Dominican Republic Brief Description of the Hematology-Oncology Service Palliative Care Pilot Program and Metronomic Therapy Dr. Robert Reid Cabral Children's
Title Cancer Drug Phase Status
Clinical Trial Identifier Title Cancer Drug Phase Status NCT01164995 Study With Wee-1 Inhibitor MK-1775 and Carboplatin to Treat p53 Mutated Refractory and Resistant Ovarian Cancer Epithelial Ovarian Cancer
Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma
Karmanos offers clinical trials for many different forms of cancer. Below are the most current clinical trials open to new participants as of this publication's issue date. If you have any questions regarding
Can ALL be managed without chemotherapy/transplant? (Position: NO) D.Hoelzer J.W.Goethe University Frankfurt
Can ALL be managed without chemotherapy/transplant? (Position: NO) D.Hoelzer J.W.Goethe University Frankfurt Barcelona, September 2012 First report of Monotherapy in childhood ALL 10/16 children with acute
CHILDHOOD CANER SURVIVOR STUDY ANALYSIS CONCEPT PROPOSAL
CHILDHOOD CANER SURVIVOR STUDY ANALYSIS CONCEPT PROPOSAL Project Title: Comparison of risks of mortality (all-cause, cause-specific) and invasive second or subsequent cancers: a Childhood Cancer Survivor
We updated the design of this site on December 18, Previous Study Return to List Next Study
We updated the design of this site on December 18, 2017. Learn more. Find Studies About Studies Submit Studies Resources About Site Trial record 1 of 1 for: AC220-A-U302 Previous Study Return to List Next
Childhood Cancer Statistics, England Annual report 2018
Childhood Cancer Statistics, England Annual report 2018 Report on behalf of the Children, Teenagers and Young Adults Expert Advisory Group, National Cancer Registration and Analysis Service 1 About Public
Cancer in adolescents and Young Adults
17 th ESO-ESMO Masterclass in Clinical Oncology 24-29 March 2018, Cancer in adolescents and Young Adults Laurence Brugières Gustave Roussy Cancer Center Villejuif, France Cancer in TYA A rare disease in
Cardio-Oncology Detection and Treatment of Chemotherapy- Induced Cardiac Dysfunction. Tochi M. Okwuosa, DO, FACC Rush University Medical Center
Cardio-Oncology Detection and Treatment of Chemotherapy- Induced Cardiac Dysfunction Tochi M. Okwuosa, DO, FACC Rush University Medical Center Epidemiology of Heart Disease in Cancer Patients Stroke Cancer
For Health Professionals Who Care For Cancer Patients
May 2014 Volume 17, Number 5 For Health Professionals Who Care For Cancer Patients Inside This Issue: Editor s Choice New Programs: Breast Trastuzumab Emtansine for Metastatic Breast Cancer (UBRAVKAD);
Medical Late Effects of Childhood Cancer
Medical Late Effects of Childhood Cancer Robert Goldsby Associate Professor of Clinical Pediatric UCSF Late Mortality in 5+ Year Survivors 1.00 US Female US Male Survival function estimate 0.70 0.75 0.80
Clinical Policy: Nivolumab (Opdivo) Reference Number: CP.PHAR.121 Effective Date: Last Review Date: Line of Business: Medicaid
Clinical Policy: (Opdivo) Reference Number: CP.PHAR.121 Effective Date: 07.15 Last Review Date: 01.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
Disturbances of female reproductive system in survivors of childhood cancer
Disturbances of female reproductive system in survivors of childhood cancer Assoc. Prof. Zana Bumbuliene VU Faculty of Medicine Clinic of Obstetrics and Gynaecology 13 SEP 2014 Introduction Cancer is the
6 TH ESO-SIOP EUROPE MASTERCLASS IN PAEDIATRIC ONCOLOGY June 2016 Berlin, Germany. Chairs: A. Eggert, DE B. Morland, UK R.
MASTERCLASS 6 TH ESO-SIOP EUROPE MASTERCLASS IN PAEDIATRIC ONCOLOGY Held with the support of 11-16 June 2016 Berlin, Germany Chairs: A. Eggert, DE B. Morland, UK R. Riccardi, IT INTRODUCTION ESO and SIOP-Europe
The Clinical Research E-News
Volume 3: ISSUE 5: March 23, 2011 The Clinical Research E-News Now Open: CALGB 90802, Randomized Phase III trial comparing everolimus plus placebo versus everolimus plus bevacizumab for advanced renal
Kymriah. Kymriah (tisagenlecleucel) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.101 Subject: Kymriah Page: 1 of 5 Last Review Date: September 20, 2018 Kymriah Description Kymriah
Acute myeloid leukemia. M. Kaźmierczak 2016
Acute myeloid leukemia M. Kaźmierczak 2016 Acute myeloid leukemia Malignant clonal disorder of immature hematopoietic cells characterized by clonal proliferation of abnormal blast cells and impaired production
National Cancer Drugs Fund List
National Cancer s Fund List (Including list of NICE approved and baseline funded drugs/indications from 1st April 2016 with criteria for use) ver1.95 20-Jul-18 NHS England INFORMATION READER BOX Directorate
PEDIATRIC CANCER IN IDAHO
PEDIATRIC CANCER IN IDAHO 2006-2015 A Publication of the ACKNOWLEDGMENTS The Idaho Hospital Association (IHA) contracts with, and receives funding from, the Idaho Department of Health and Welfare, Division